Basilea Pharmaceutica (SIX: BSLN)

Last close As at 05/08/2026

CHF50.70

0.20 (0.40%)

Market capitalisation

CHF681m

Basilea Pharmaceutica is focused on treating infectious diseases; its marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA antibiotic). In late 2023, it expanded its pipeline to include fosmanogepix, BAL2062 and tonabacase. In January 2024, it acquired the preclinical LptA inhibitor antibiotics programme from Spexis.

Latest Insights

View More
misael-moreno-fN6K30xtiKE-unsplash-Basilea

Market Data

Share Price CHF50.70
Market Cap CHF681m
52-Week High CHF59.20
52-Week Low CHF44.70
% Change 1M (5.6)
% Change 6M (12.0)
% Change 12M (9.0)
Ave. Daily Volume 1yr 34,166

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Adesh Kaul

    CFO

  • David Veitch

    CEO

Share Price Chart

Further insights

insight

Healthcare

Antibiotic resistance

insight

Healthcare

Antibiotics

Thematics

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.